{"entity":{"id":"nct02286687","kind":"trial","name":"Talazoparib molecular basket in advanced cancers","aka":[],"tldr":"This closed study tested talazoparib in advanced cancers with selected DNA-repair or PTEN alterations. Its published somatic-BRCA results come from a small mixed-cancer cohort.","summary":"Registry active not recruiting, last updated 2026-06-12. Advanced cancers with BRCA1/2, selected other DNA-repair or PTEN alterations. The registry enrollment is estimated at 150; the 2024 publication reports 79 treated participants and 18 in the somatic BRCA1/2 cohort. These are different populations, not conflicting efficacy denominators. No current enrollment route.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT02286687","url":"https://clinicaltrials.gov/study/NCT02286687"}],"tags":[],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["talazoparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-piha-paul-talazoparib-ddr-npj-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02286687","phase":"2","setting":"Advanced cancers with BRCA1/2, selected other DNA-repair or PTEN alterations","sponsor":"M.D. Anderson Cancer Center","started":"2014-12-22","startedType":"actual","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02286687/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/"}],"paper":[{"id":"paper-piha-paul-talazoparib-ddr-npj-2024","kind":"paper","name":"Talazoparib in advanced cancers with BRCA1/2, DNA repair and PTEN alterations","route":"/key-papers/paper-piha-paul-talazoparib-ddr-npj-2024/"}]}}